We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Arecor Therapeutics Plc | LSE:AREC | London | Ordinary Share | GB00BMWLM973 | ORD GBP0.01 |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 136.50 | 133.00 | 140.00 | 136.50 | 136.50 | 136.50 | 19,481 | 08:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Coml Physical, Biologcl Resh | 3.54M | -9.26M | -0.3024 | -4.51 | 41.8M |
TIDMAREC
RNS Number : 9539A
Arecor Therapeutics PLC
07 June 2021
Arecor Therapeutics plc
("Arecor", the "Company" or the "Group")
EXCLUSIVE FORMULATION STUDY COLLABORATION WITH PAR STERILE PRODUCTS TO DEVELOP
A STABLE READY TO USE PRODUCT
Cambridge, UK, 7(th) June 2021: Arecor Therapeutics plc (AIM: AREC) , the biopharmaceutical company advancing today's therapies to enable healthier lives, today announces that it has signed a formulation study agreement with Par Sterile Products, LLC, an Endo International plc company ("Par").
Under this agreement, Arecor will use its proprietary formulation technology platform Arestat(TM) to develop a differentiated, stable, single dose, Ready-to-Use ("RTU") formulation of one of Par's products for intravenous administration. The new product formulation supports safe medication practices and operational efficiency by eliminating the need for reconstitution. Par will fund the development work and has the option to acquire the rights to the new proprietary formulation and associated Intellectual Property under a technology licensing model (with associated potential milestone and royalty payments) to further develop and commercialise the product.
Arestat(TM) is an innovative and proprietary formulation technology platform which enhances the properties of therapeutic proteins, peptides and vaccines. Arecor applies the Arestat(TM) technology to deliver superior reformulations of existing products as well as improving properties of new products in development.
Sarah Howell, Chief Executive Officer of Arecor, said: " We are delighted to be collaborating with Par on an additional programme which further strengthens our track record in developing RTU medicines. This growing partnership supports both companies' product development strategies to bring enhanced products to market that simplify care and improve patient outcomes. We believe that our Arestat(TM) technology has the potential to deliver a new formulation that can support safe medication practices and improve healthcare efficiency to benefit patients. We look forward to developing this relationship with Par which augments our partnership portfolio of major pharmaceutical companies and demonstrates how our formulation expertise can provide novel solutions for our partners."
This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014 (MAR)
-ENDS-
For more information, please contact:
Arecor Therapeutics plc www.arecor.com Dr Sarah Howell, Chief Executive Tel: +44 (0) 1223 426060 Officer Email: info@arecor.com Susan Lowther, Chief Financial Officer Tel: +44 (0) 1223 426060 Email: info@arecor.com Mo Noonan, Communications Tel: +44 (0) 7876 444977 Email: mo.noonan@arecor.com Panmure Gordon (UK) Limited (NOMAD Tel: +44 (0) 20 7886 2500 and Broker) Freddy Crossley, Emma Earl (Corporate Finance) Rupert Dearden (Corporate Broking) Consilium Strategic Communications Chris Gardner, David Daley, Angela Tel: +44 (0) 20 3709 5700 Gray Email: arecor@consilium-comms.com
Notes to Editors
About Arecor
Arecor Therapeutics plc is a biopharmaceutical company transforming patient care by bringing innovative medicines to market. Through the enhancement of existing medicines using our Arestat(TM) technology, we are developing a broad portfolio of therapies as part of our proprietary pipeline and through partnerships with leading pharmaceutical and biotech companies. Our treatments for people living with chronic disease are designed to simplify patient care and improve medication adherence.
For further details please see our website, www.arecor.com
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
AGRFFMPTMTBMBJB
(END) Dow Jones Newswires
June 07, 2021 02:00 ET (06:00 GMT)
1 Year Arecor Therapeutics Chart |
1 Month Arecor Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions